U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799039) titled 'Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease' on Jan. 23.
Brief Summary: This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the IBD patient population.
Study Start Date: Sept. 01, 2025
Study Type: INTERVENTIONAL
Condition:
C. Diff
IBD
Intervention:
DRUG: Xylitol
Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bri...